Prescient Therapeutics to Work with Peter MacCallum Cancer Centre to Advance Promising New Personalised Cancer Therapies

- **Research program with world-class cell therapy institute and Professor Phil Darcy**
- **Second addition to Cell Therapy Enhancement Program**
- **Prescient to retain resultant intellectual property**

MELBOURNE Australia 14 August 2020: Prescient Therapeutics Limited (ASX: PTX; Prescient), a clinical-stage company developing new targeted cancer therapies, today announced a research collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) to develop new cell therapy technologies, including CAR-T technologies. Under the terms of the research contract, Prescient will own resultant intellectual property (IP) from the research program being led by Peter Mac's Professor Phil Darcy.

CAR-T is a type of cellular therapy that reprograms the immune cells of a cancer patient to recognise and destroy cancer.

The research program, being undertaken in Professor Darcy's laboratory at Peter Mac, is an important addition to the Cell Therapy Enhancements (CTE) programs in Prescient's pipeline. In a similar manner to the CTE program underway with Carina Biotech, this research program with Peter Mac will seek to produce technologies that can complement existing CAR-T approaches. The aim of Prescient's CTE programs is to create efficacy and efficiency enhancements that are relevant to third parties in the cell therapy field (namely CAR-T), which may incorporate these into their own programs under license.

Prescient will retain its previously developed IP and look to extend this portfolio through this collaboration with Peter Mac.

Professor Phil Darcy, Laboratory Head of Cancer Immunotherapy at Peter Mac said: "CAR-T therapy has shown strong therapeutic activity in certain haematological malignancies however the effects in solid cancers have been poor to date. The approach we are exploring with Prescient may reprogram the tumour microenvironment that results in significantly enhancing CAR T cell anti-tumour activity."

Prescient Therapeutics CEO Steven Yatomi-Clarke said, “We are working against time for many cancer patients, so joining with the world-leading experts in this field at Peter Mac will greatly enhance our collective efforts to advance these new treatments and get them to patients who will potentially benefit. Prescient is the only ASX listed company developing CAR-T programs and this is an important strategic initiative to complement our programs in Cell Therapy Enhancements. We look forward to working closely with Peter Mac as we employ our knowledge of targeted therapies and growing standing in cellular therapies to generate technologies that will be relevant for the CAR-T field.”

The Melbourne-based Peter MacCallum Cancer Centre is an internationally recognised research and clinical leader in new treatment for cancer.

Peter Mac Executive Director Dominic Wall said: “Our clinical and research teams are world leaders in this promising field and we are excited be working with an Australian company that shares our goals.”

– Ends –

Share Purchase Plan

PTX is currently conducting a Share Purchase Plan (SPP) at 5.5c. The SPP closes on 17 August 2020 at 5pm AEST. To request your personalised SPP forms click here: https://prescienttherapeutics.investorportal.com.au/request-forms/

Investor briefing

PTX will host an investor briefing today at 11am AEST to provide investors with an overview of recent news flow and progress by the company. To register for the briefing click here: https://prescienttherapeutics.investorportal.com.au/shareholderbriefing/

Find out more at ptxtherapeutics.com, or connect with us via Twitter @PTX_AUS and LinkedIn.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR’s modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.

OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Cell Therapy: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

COVID-19 Therapies

Two assets are being assessed by the Doherty Institute for antiviral activity against SARS-CoV-2, the virus that causes COVID-19 disease.

Find out more at ptxtherapeutics.com, or connect with us via Twitter @PTX_AUS and LinkedIn.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Steven Yatomi-Clarke	**Investor enquiries:**	**Media enquiries:**
CEO & Managing Director	Warrick Lace – Reach Markets	Andrew Geddes – CityPR
Prescient Therapeutics	+61 404 656 408	+61 2 9267 4511
steven@ptxtherapeutics.com	warrick.lace@reachmarkets.com.au	ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in

new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : Supplemental COVID-19 Risk Factors